ADHD pills lead to other drugs, hormone therapy guidelines have been updated and Novo Nordisk and Eli Lilly cut obesity drug prices. Read more in this week's WSJ Health newsletter:

Core Insights - The article discusses new hormone therapy guidelines, advancements in breast cancer medications, and price reductions for obesity drugs, highlighting significant developments in the healthcare sector [1] Group 1: Hormone Therapy Guidelines - New guidelines for hormone therapy have been introduced, aiming to improve treatment protocols and patient outcomes [1] Group 2: Breast Cancer Medications - There are updates on breast cancer pills, indicating progress in treatment options that may enhance efficacy and patient adherence [1] Group 3: Obesity Drug Price Cuts - The article notes price cuts for obesity drugs, which could increase accessibility and potentially expand the market for these treatments [1]